Streetbeat News

Products Services

MSFT

Microsoft's subsidiary, Nuance Communications, announced its AI-powered clinical notes application, DAX Express, is coming to Epic Systems to help reduce physicians’ administrative workloads. Epic Systems is a healthcare software company that helps hospitals and other health systems store, share, and access electronic health records. DAX Express can record a conversation between a doctor and a patient in real time and create a note using a combination of existing artificial intelligence and OpenAI’s newest model, GPT-4. The technology is saving clinicians around 7 minutes per patient encounter.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 7:54 pm

MSSTF

Mindset Pharma (OTCQB:MSSTF) has received approval from the UK's Medicines and Healthcare Products Regulatory Authority to begin a Phase 2 clinical study on its novel psilocin prodrug, MSP-1014, for the treatment of Major Depressive Disorder. The study will assess the safety and efficacy of MSP-1014 and is expected to provide a strong efficacy signal for the drug. The company's CEO sees this as a significant step towards becoming a clinical-stage biotech company focused on novel and patentable psychedelic-inspired therapeutics.

Portfolio Pulse from Lara Goldstein

June 27, 2023 | 7:54 pm

T

DirecTV has signed a multi-year renewal with the NFL, which includes carriage of the NFL Redzone across all platforms for the first time.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 7:46 pm

NKTX

Nkarta Inc's Phase 1 study of NKX101 for treating acute myeloid leukemia (AML) has been deemed a setback by Needham, leading to a revised development timeline and a lowered price target from $26 to $19. The company plans to enroll more patients in the trial and provide an update in 1H 2024. NKTX shares are down 35.50% at $2.92.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 7:13 pm

REGN

The U.S. Food and Drug Administration (FDA) has declined to approve a higher-dose version of Regeneron Pharmaceuticals' Eylea treatment. This decision could impact Regeneron's ability to compete against fast-gaining rivals in the eye drug market.

Portfolio Pulse from Happy Mohamed

June 27, 2023 | 6:55 pm

MSFT

NTDOY

SONY

Nintendo's President Shuntaro Furukawa announced that Nintendo Accounts will be used to facilitate a smooth transition for users from the Nintendo Switch to the company's upcoming console. There are currently over 290 million active Nintendo Accounts across console and mobile platforms. This move aligns Nintendo with industry leaders such as Sony and Microsoft, who have successfully transitioned users' accounts across hardware generations. Despite a decline in Switch sales, Nintendo maintains that the current console has at least another year of relevance.

Portfolio Pulse from Franca Quarneti

June 27, 2023 | 6:40 pm

GNRC

Generac Holdings Inc. (NYSE:GNRC) shares are trading higher due to increased demand for backup generators in Texas, correlated to the strain on the state’s main electric grid due to intense heat. The company's shares hit a four-month high last week amid the Texas grid operator urging residents to conserve electricity to prevent blackouts. Shares of GNRC were up 9.11% at $142.95 at the time of publication.

Portfolio Pulse from Ryan Gustafson

June 27, 2023 | 6:15 pm

GM

TSLA

General Motors (GM) and Tesla (TSLA) have partnered for EV charging, despite being competitors in the EV market. GM will integrate the North American Charging Standard (NACS) connector into its EVs, expanding access to charging for GM EV drivers at 12,000 Tesla Supercharger stations. The Tesla Supercharger Network will be open to GM EV drivers starting in 2024. GM CEO Mary Barra views Elon Musk as both a competitor and a partner.

Portfolio Pulse from Adam Eckert

June 27, 2023 | 6:14 pm

RPD

Rapid7 has announced that its InsightIDR product now supports AWS AppFabric. This will allow users to detect and respond to threats across their AWS environment more effectively.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 6:13 pm

MRK

PFE

Merck & Co Inc and Ridgeback Biotherapeutics have withdrawn their COVID-19 pill application in the European Union due to regulatory hurdles and insufficient data. The drug's effectiveness, at only 30%, has been overshadowed by Pfizer Inc.'s COVID drug, Paxlovid, which has nearly 90% effectiveness. Merck expects a significant decline in sales of the drug, Lagevrio, in FY23, down to approximately $1.0 billion from $5.7 billion in 2022.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 6:06 pm